Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Coates

Showing results (391-400 of 455) with videos related to

Pageof 46
Sort By:
Journal of the National Cancer Institute|November 2, 2006
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assaysMeredith M Regan, Giuseppe Viale, Mauro G Mastropasqua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 StudySigne Borgquist, Anita Giobbie-Hurder, Thomas P Ahern, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VIGünther Gruber, Marco Bonetti, M Laura Nasi, et al.
Journal of the National Cancer Institute|January 31, 2008
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerGiuseppe Viale, Meredith M Regan, Mauro G Mastropasqua, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2018
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II TrialSilvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98Giuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialDiana Crivellari, Kathryn P Gray, Silvia Dellapasqua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Pageof 46

Showing results (391-400 of 455) with videos related to

Sort By:
Pageof 46
Journal of the National Cancer Institute|November 2, 2006
Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assaysMeredith M Regan, Giuseppe Viale, Mauro G Mastropasqua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 6, 2017
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 StudySigne Borgquist, Anita Giobbie-Hurder, Thomas P Ahern, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 11, 2016
Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trialN Zdenkowski, J F Forbes, F M Boyle, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2005
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VIGünther Gruber, Marco Bonetti, M Laura Nasi, et al.
Journal of the National Cancer Institute|January 31, 2008
Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancerGiuseppe Viale, Meredith M Regan, Mauro G Mastropasqua, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2017
Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFTM M Regan, B A Walley, P A Francis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 28, 2018
Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II TrialSilvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2007
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98Giuseppe Viale, Meredith M Regan, Eugenio Maiorano, et al.
Breast (Edinburgh, Scotland)|March 5, 2013
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a "standard chemotherapy regimen": the CASA randomized trialDiana Crivellari, Kathryn P Gray, Silvia Dellapasqua, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 11, 2007
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancerPer Karlsson, Bernard F Cole, Karen N Price, et al.
Pageof 46